Hydrotalcite 500mg/5ml oral suspension
Chemical compound used in medicine
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Hydrotalcite
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Hydrotalcite
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 7 · 1980–2024
Showing all 30 studies, sorted by most relevant.
U. Sikander, S. Sufian, M. Salam
International Journal of Hydrogen Energy, 2017
E. Bernard, W. Zucha, B. Lothenbach, et al.
Cement and Concrete Research, 2022
MgO contained in cementitious materials is experimentally observed to precipitate as poorly crystalline hydrotalcite (Mg-Al LDH). However, the geochemical modelling of hydrotalcite is challenging due to the lack of consistent thermodynamic dataset for this phase. Hydrotalcites with Mg/Al = 2 were synthesised in the presence of NaHCO3, NaCl, Na2SO4, NaNO3, and NaOH. Mass balance, XRD and FT-IR indicated the incorporation of the anions in the interlayer together with some carbonate. The crystallinity of the phase increased depending on the anion: SO42− < Cl− < NO3− < OH− < CO32−. An in-situ increase of temperature monitored by XRD and TGA showed that the stability of the hydrotalcite structure with temperature also depended on the incorporated anion. The solubility products were calculated based on the solution analysis of samples re-equilibrated at different temperatures, while the entropy and heat capacity were obtained from the additivity method or the molar volume. A simple solid-solution model for hydrotalcite containing CO3, OH, SO4, Cl and NO3 is suggested.
Abstract licence: CC BY
R. Dębek, M. Motak, T. Grzybek, et al.
Catalysts, 2017
Nickel-containing hydrotalcite-derived materials have been recently proposed as promising materials for methane dry reforming (DRM). Based on a literature review and on the experience of the authors, this review focuses on presenting past and recent achievements on increasing activity and stability of hydrotalcite-based materials for DRM. The use of different NiMgAl and NiAl hydrotalcite (HT) precursors, various methods for nickel introduction into HT structure, calcination conditions and promoters are discussed. HT-derived materials containing nickel generally exhibit high activity in DRM; however, the problem of preventing catalyst deactivation by coking, especially below 700 °C, is still an open question. The proposed solutions in the literature include: catalyst regeneration either in oxygen atmosphere or via hydrogasification; or application of various promoters, such as Zr, Ce or La, which was proven to enhance catalytic stability.
Abstract licence: CC BY
Jun Zhang, Jinzhu Chen
ACS Sustainable Chemistry & Engineering, 2017
F. Cavani, F. Trifiró, A. Vaccari
Catalysis Today, 1991
A. Machner, M. Zając, Mohsen Ben Haha, et al.
Cement and Concrete Research, 2018
Yuan Tan, X. Y. Liu, Leilei Zhang, et al.
Angewandte Chemie, 2017
Juntian Niu, Shirley E. Liland, Jia Yang, et al.
Chemical Engineering Journal, 2019
A. Machner, M. Zając, Mohsen Ben Haha, et al.
Cement and Concrete Research, 2018
Wenji Jin, Dongki Lee, Yukwon Jeon, et al.
Minerals, 2020
Biocompatible hydrotalcite nanohybrids, i.e., layered double hydroxide (LDH) based nanohybrids have attracted significant attention for biomedical functions. Benefiting from good biocompatibility, tailored drug incorporation, high drug loading capacity, targeted cellular delivery and natural pH-responsive biodegradability, hydrotalcite nanohybrids have shown great potential in drug/gene delivery, cancer therapy and bio-imaging. This review aims to summarize recent progress of hydrotalcite nanohybrids, including the history of the hydrotalcite-like compounds for application in the medical field, synthesis, functionalization, physicochemical properties, cytotoxicity, cellular uptake mechanism, as well as their related applications in biomedicine. The potential and challenges will also be discussed for further development of LDHs both as drug delivery carriers and diagnostic agents.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
70 found
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 415 interactions
ATC A02AD04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Hydrotalcite
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure

ATC classifications (Wikidata)
Linked open data from Wikidata (Q9003473), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.